Lost in translation: Implications of HIV-1 codon usage for immune escape and drug resistance

AIDS Reviews

Volumn 6, Issue 1, 2004, Pages 54-60

  Kijak, Gustavo H ^a   Currier, Jeffrey R ^a   Tovanabutra, Sodsai ^a   Cox, Josephine H ^a   Michael, Nelson L ^b   Wegner, Scott A ^b   Birx, Deborah L ^b   McCutchan, Francine E ^a  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Condon usage; Drug resistance; HIV evolution; Immune escape

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; EVOLUTION; GENETIC CODE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; REVERTANT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON; VIRUS RESISTANCE; VIRUS SURVIVAL; WILD TYPE;

ANTI-HIV AGENTS; CODON; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PROTEIN BIOSYNTHESIS;

EID: 2342608022     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Barre-Sinoussi F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71.
2. Gallo R, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983;220:865-7.
3. Gallo R. Historical essay. The early years of HIV/AIDS. Science 2002;298:1728-30.
4. Montagnier L. Historical essay. A history of HIV discovery. Science 2002;298:1727-8.
5. Fauci A. HIV and AIDS: 20 years of science. Nat Med 2003;9: 839-43.
6. Berger E, Murphy P, Farber J. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
7. Mascola J, Montefiori D. HIV-1: natures master of disguise. Nat Med 2003;9:393-4.
8. Klenerman P, Wu Y, Phillips R. HIV: current in escapology. Curr Opin Microbiol 2002;5:408-13.
9. Brander C, Walker B. Gradual adaptation of HIV to human host populations: good or bad news? Nat Med 2003;1359-62.
10. Deeks S. International perspectives on atiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 2001;26(Suppl 1):25-33.
11. Miller V. International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J Acquir Immune Defic Syndr 2001;26(Suppl 1):34-50.
12. Loveday C. International perspectives on antiretroviral resistance. Nucleoside reverse transciptase inhibitor resistance. J Acquir Immune Defic Syndr 2001;26(Suppl 1):10-24.
13. Mansky L, Temin H. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from fidelity of purified reverse transcriptase. J Virol 1995;69:5087-94.
14. Burke D. Recombination in HIV: an important viral evolutionary strategy. Emerg Infect Dis 1997;3:253-9.
15. Wei X, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
16. Ho D, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
17. Eigen M, Biebricher C. Sequence space and quasispecies distribution. In: Domingo E, Holland J, Ahlquist P (eds). RNA genetics. Vol III. Boca Raton, Fla: CRC Press Inc 1998:3-22.
18. Holland J. De la Torre J. Steinhauer D. RNA virus populations as quasispecies. Curr Top Microbiol Immunol 1992;176:1-20.
19. Coffin J. HIV population dynamics in vivo: implications for genetic variation pathogenesis, and therapy. Science 1995;267:483-9.
20. Nei M, Kumar S. Molecular evolution and phylogenetics. Oxford UK: Oxford University Press 2000.
21. Lewin B. Genes VIII. Oxford, UK: Oxford University Press 2000.
22. Yang Z, Bielawski J. Statistical methods for detection molecular adaptation. Trends in Ecology and Evolution 2000;15:496-503.
23. Hughes A. Adaptative evolution of genes and genous. Oxford, UK: Oxford University Press 1999.
24. Soudeyns H, et al. Selective pressure exerted by immunodominant HIV-1-specific cytotoxic T lymphocyte responses during primary infection drives genetic variation restricted to the epitope . Eur J Immunol 1999;29:3629-35.
25. Yang W, Bielawski J, Yang Z. Widespread adaptive evolution in the human immunodeficiency virus type 1 genome. J Mol Evol 2003;57: 212-21.
26. Sa-Filho D, et al. Analysis of the protease sequences of HIV-1 infected individuals after Indinavir monotherapy. J Clin Virol 2003;28: 186-202.
27. Grantham R, Gautier C, Gouy M, Mercier R, Pave A. Codon catalog usage and the genome hypothesis. Nucleic Acids Res 1980;8: r49-r62.
28. Ikemura T. Correlation between the abudance of Escherichia coli transfer RNAs the occurrence of the respective codons in its protein genes: a proposal for a synonymous codon choice that is optimal for the E. coli translational system. J Mol Biol 1981;151:389-409.
29. Bernardi G. The vertebrate genome: isochores and evolution. Mol Biol Evol 1993;10:186-204.
30. Van Hermert F, Berkhout B. The tendency of lentiviral open reading frames to become A-rich: constraints imposed by viral genome organization and cellular tRNA availability. J Mol Evol 1995;41:132-40.
31. Oliver J, Marin A. A relationship between GC content and coding-sequence length. J Mol Evol 1996;43:216-23.
32. Adkins J, Noble S. Efavirenz. Drugs 1998;56:1055-64; discussion 1065-6.
33. McCutchan F. Understanding the genetic diversity of HIV-1. Aids 2000;14(Suppl 3):31-44.
34. Peeters M, Sharp PM. Genetic diversity of HIV-1: the moving target Aids 2000;14(Suppl 3):129-40.
35. Van Harmelen J, et al. A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations. AIDS Res Hum Retroviruses 199;15:395-8.
36. Loemba H, et al. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother 2002;46:208794.
37. Brenner B, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. Aids 2003;17:1-5.
38. Gurusinghe A, et al. Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. J Med Virol 1995;46:238-43.
39. Hooker D, et al. An in vivo mutation from to typtophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes. J Virol 1996;70:8010-8.
40. Rhee S, et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003;31:298-303.
41. Shirasaka T, et al. Emergence of human immunodeficiecny virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995;92:2398-402.
42. García-Lerma J, Gerrish P, Wright A, Qari S, Heneine W. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1. J Virol 2000;74:9339-46.
43. McMichael A, Rowland-Jones S. Cellular immune responses to HIV. Nature 2001;410:980-7.
44. HIV Sequence Database LANL, Los Alamos, NM (http://hiv-web.lanl.gov). Accessed 12 November 2003.
45. Harrer T, et al. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term non-progressing HIV-1-infected individual. J Immunol 1998;161:4875-81.
46. Fukada K, et al. Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients. Aids 2002;16:701-11.
47. Kubo R, et al. Definition of specific peptide for four major HLA-LA alleles. J Immunol 1994;152:3913-24.
48. Yusim K, et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 2002;76:8757-68.
49. Moore C, et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002;296:1439-43.
50. Thomson M, Pérez-Álvarez L. Náiera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2002;2:461-71.